4JV6
The crystal structure of PDE6D in complex to inhibitor-1
4JV6 の概要
エントリーDOI | 10.2210/pdb4jv6/pdb |
関連するPDBエントリー | 4JV8 4JVB 4JVF |
分子名称 | Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit delta, 1-benzyl-2-phenyl-1H-benzimidazole (3 entities in total) |
機能のキーワード | immunoglobulin-like beta-sandwich, gdi-like solubilizing factor, prenyl binding protein, protein binding-inhibitor complex, protein binding/inhibitor |
由来する生物種 | Homo sapiens (human) |
タンパク質・核酸の鎖数 | 1 |
化学式量合計 | 18153.83 |
構造登録者 | Gunther, Z.,Papke, B.,Ismail, S.,Vartak, N.,Chandra, A.,Hoffmann, M.,Hahn, S.,Triola, G.,Wittinghofer, A.,Bastiaens, P.,Waldmann, H. (登録日: 2013-03-25, 公開日: 2013-05-22, 最終更新日: 2023-09-20) |
主引用文献 | Zimmermann, G.,Papke, B.,Ismail, S.,Vartak, N.,Chandra, A.,Hoffmann, M.,Hahn, S.A.,Triola, G.,Wittinghofer, A.,Bastiaens, P.I.,Waldmann, H. Small molecule inhibition of the KRAS PDEd interaction impairs oncogenic KRAS signalling Nature, 497:638-642, 2013 Cited by PubMed Abstract: The KRAS oncogene product is considered a major target in anticancer drug discovery. However, direct interference with KRAS signalling has not yet led to clinically useful drugs. Correct localization and signalling by farnesylated KRAS is regulated by the prenyl-binding protein PDEδ, which sustains the spatial organization of KRAS by facilitating its diffusion in the cytoplasm. Here we report that interfering with binding of mammalian PDEδ to KRAS by means of small molecules provides a novel opportunity to suppress oncogenic RAS signalling by altering its localization to endomembranes. Biochemical screening and subsequent structure-based hit optimization yielded inhibitors of the KRAS-PDEδ interaction that selectively bind to the prenyl-binding pocket of PDEδ with nanomolar affinity, inhibit oncogenic RAS signalling and suppress in vitro and in vivo proliferation of human pancreatic ductal adenocarcinoma cells that are dependent on oncogenic KRAS. Our findings may inspire novel drug discovery efforts aimed at the development of drugs targeting oncogenic RAS. PubMed: 23698361DOI: 10.1038/nature12205 主引用文献が同じPDBエントリー |
実験手法 | X-RAY DIFFRACTION (1.87 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード
